Bosentan Therapy for Pulmonary Arterial Hypertension
Top Cited Papers
Open Access
- 21 March 2002
- journal article
- clinical trial
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 346 (12), 896-903
- https://doi.org/10.1056/nejmoa012212
Abstract
Endothelin-1 is a potent vasoconstrictor and smooth-muscle mitogen. In a preliminary study, the orally administered dual endothelin-receptor antagonist bosentan improved exercise capacity and cardiopulmonary hemodynamics in patients with pulmonary arterial hypertension. The present trial investigated the effect of bosentan on exercise capacity in a larger number of patients and compared two doses.Keywords
This publication has 16 references indexed in Scilit:
- Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebocontrolled studyThe Lancet, 2001
- Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin AnalogueNew England Journal of Medicine, 2000
- Primary Pulmonary HypertensionNew England Journal of Medicine, 1997
- A Comparison of Continuous Intravenous Epoprostenol (Prostacyclin) with Conventional Therapy for Primary Pulmonary HypertensionNew England Journal of Medicine, 1996
- Endothelin and Collagen Vascular Disease: A Review with Special Reference to Raynaud's Phenomenon and Systemic Sclerosis.Internal Medicine, 1994
- Expression of Endothelin-1 in the Lungs of Patients with Pulmonary HypertensionNew England Journal of Medicine, 1993
- The Effect of High Doses of Calcium-Channel Blockers on Survival in Primary Pulmonary HypertensionNew England Journal of Medicine, 1992
- Pulmonary hypertension in the crest syndrome variant of systemic sclerosisArthritis & Rheumatism, 1986
- Primary pulmonary hypertension: natural history and the importance of thrombosis.Circulation, 1984
- Prevalence and clinical correlates of pulmonary arterial hypertension in progressive systemic sclerosisAmerican Journal Of Medicine, 1983